In conclusion NF experts and patient representatives consent to prioritise the development of future clinical trials for new drug treatments for MPNST, benign peripheral nerve sheath tumours, cutaneous manifestations and high grade gliomas for NF1; tumour manifestations for NF2; and pain for SWN. The gene discussed is NF2; the disease is central nervous system cancer.